Literature DB >> 22712545

Colonic neoplasia in young patients with inflammatory bowel disease and primary sclerosing cholangitis.

M H Imam1, E W Thackeray, K D Lindor.   

Abstract

AIM: Current guidelines recommend annual surveillance for colorectal cancer (CRC) in all patients with inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC). The aim of our study was to validate the need for annual surveillance for colon neoplasia in patients ≤45 of age with a combined diagnosis of PSC and IBD.
METHOD: We identified patients, ≤45 years of age with a combined diagnosis of PSC and IBD, who were seen at the Mayo Clinic between 1995 and 2010. We then reviewed the medical records of the patients who developed colonic neoplasia defined as cancer, high-grade dysplasia (HGD) or dysplasia-associated lesion or mass (DALM).
RESULTS: In the population of 784 patients ≤45 years of age with a combined diagnosis of PSC and IBD, 10 (1.3%) of 784 developed colonic neoplasia during the follow-up period. Seven patients had colon cancer, one had HGD and two had a DALM.
CONCLUSION: Colonic neoplasia is uncommon in young patients (≤45 years of age) with a combined diagnosis of PSC and IBD. We suggest delaying surveillance in young patients and propose that studies should be carried out to clarify the cost-effectiveness of annual or biannual surveillance colonoscopies according to patient age.
© 2012 The Authors. Colorectal Disease © 2012 The Association of Coloproctology of Great Britain and Ireland.

Entities:  

Mesh:

Year:  2013        PMID: 22712545     DOI: 10.1111/j.1463-1318.2012.03133.x

Source DB:  PubMed          Journal:  Colorectal Dis        ISSN: 1462-8910            Impact factor:   3.788


  4 in total

Review 1.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

2.  MTG16 is a tumor suppressor in colitis-associated carcinoma.

Authors:  Elizabeth M McDonough; Caitlyn W Barrett; Bobak Parang; Mukul K Mittal; J Joshua Smith; Amber M Bradley; Yash A Choksi; Lori A Coburn; Sarah P Short; Joshua J Thompson; Baolin Zhang; Shenika V Poindexter; Melissa A Fischer; Xi Chen; Jiang Li; Frank L Revetta; Rishi Naik; M Kay Washington; Michael J Rosen; Scott W Hiebert; Keith T Wilson; Christopher S Williams
Journal:  JCI Insight       Date:  2017-08-17

Review 3.  Update on inflammatory bowel disease in patients with primary sclerosing cholangitis.

Authors:  Christos Tsaitas; Anysia Semertzidou; Emmanouil Sinakos
Journal:  World J Hepatol       Date:  2014-04-27

Review 4.  Worldwide Incidence of Colorectal Cancer, Leukemia, and Lymphoma in Inflammatory Bowel Disease: An Updated Systematic Review and Meta-Analysis.

Authors:  Chelle L Wheat; Kindra Clark-Snustad; Beth Devine; David Grembowski; Timothy A Thornton; Cynthia W Ko
Journal:  Gastroenterol Res Pract       Date:  2016-05-16       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.